conference overview

It is well established that cardiovascular disease (CVD) is more frequent in chronic kidney disease (CKD). In particular, patients with CKD are predisposed to heart rhythm disorders. CKD patients may present with a wide spectrum of arrhythmias ranging from supraventricular arrhythmias and ectopics, atrial fibrillation and flutter, ventricular ectopics and sustained and non-sustained ventricular tachycardia, and sudden cardiac death (SCD). There is a strong public health and economic imperative to improve outcomes for people with kidney disease and heart rhythm disorders. However, treatment guidelines that specifically address this population are limited.

To this end, this KDIGO conference gathered a global panel of multidisciplinary clinical and scientific expertise (e.g., nephrology, cardiology & cardiac electrophysiology, pharmacology, neurology, etc.) to identify key issues relevant to the optimal prevention, management and treatment of arrhythmias and their complications in patients with kidney disease. The objective of this conference was to assess our current state of knowledge related to the epidemiology of atrial fibrillation and stroke in kidney disease; stroke prevention in atrial fibrillation and CKD; prognostication and prevention of SCD in CKD; maintenance of electrolyte homeostasis in CKD and dialysis, particularly hyperkalemia; and rate versus rhythm control in atrial fibrillation in CKD.

The KDIGO Controversies Conference on CKD & Arrhythmias took place in Berlin, Germany on October 27-31, 2016. Drs. Mintu Turakhia of Stanford University School of Medicine, USA, and Christoph Wanner of the University of Würzburg Hospital, Germany, co-chaired this conference.